You are here

Interview with Dr. Sylvie Menard, Istituto Nazionale Tumori Milan, Italy


Dr. Carla Ripamonti is interviewing Dr. Sylvie Menard at the TAO Oncology meeting, Hopital Georges Pompidou, Paris, November 2013, on the toxicity of chemotherapy versus targeted therapy. Dr. Menard explains that although chemotherapy usually results in a more severe toxicity, these effects last a relatively short time. With targeted therapy the toxicity may be low, and the side effects less severe, but these will last for a longer period. Furthermore, targeted therapy can not (yet) replace chemotherapy, so both toxicities are experienced. E.g. with fatigue, which can be completely disabling the patient, this is an issue. Finally, as identification of patients that will respond to treatment is difficult, it is hard for patients to accept the effects on their QoL when they are not sure it will have the desired effect.

Search this site

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

NEW! Free access to the digital version of a new publication in Cancer Supportive Care

Cancer cachexia: mechanisms and progress in treatment

Authors: Egidio Del Fabbro, Kenneth Fearon, Florian Strasser

This book was supported by an educational grant from Helsinn Healthcare SA.

Featured videos

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo